Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.
Human respiratory syncytial virus (RSV) and parainfluenza virus type 3 (HPIV3) are among the most common viral causes of childhood bronchiolitis and pneumonia worldwide, and lack effective antiviral drugs or vaccines. Recombinant (r) HPIV3 was modified to express the RSV fusion (F) glycoprotein, the...
Main Authors: | Xueqiao Liu, Bo Liang, Xiang Liu, Emerito Amaro-Carambot, Sonja Surman, Peter D Kwong, Barney S Graham, Peter L Collins, Shirin Munir |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0228572 |
Similar Items
-
The C proteins of human parainfluenza virus type 1 block IFN signaling by binding and retaining Stat1 in perinuclear aggregates at the late endosome.
by: Henrick Schomacker, et al.
Published: (2012-01-01) -
Shedding course of bovine respiratory syncytial virus and bovine parainfluenza 3 virus in calves vaccinated intranasally
by: Socha Wojciech, et al.
Published: (2013-12-01) -
Effects of human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and influenza virus on CD4+ T cell activation by dendritic cells.
by: Cyril Le Nouën, et al.
Published: (2010-11-01) -
Virion-Associated Cholesterol Regulates the Infection of Human Parainfluenza Virus Type 3
by: Qiaopeng Tang, et al.
Published: (2019-05-01) -
Respiratory syncytial virus and parainfluenza Type 3 virus infections in cattle
by: Watt, N. J.
Published: (1983)